

Cervical Intraepithelial Neoplasia (CIN) - Pipeline Review, H2 2019

<https://marketpublishers.com/r/C9B17F35E21EN.html>

Date: December 2019

Pages: 133

Price: US\$ 2,000.00 (Single User License)

ID: C9B17F35E21EN

Abstracts

Cervical Intraepithelial Neoplasia (CIN) - Pipeline Review, H2 2019

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Cervical Intraepithelial Neoplasia (CIN) - Pipeline Review, H2 2019, provides an overview of the Cervical Intraepithelial Neoplasia (CIN) (Women's Health) pipeline landscape.

Cervical intraepithelial neoplasia (CIN), also known as cervical dysplasia is characterized by abnormal appearance of cells on the surface of the cervix. Cervical dysplasia usually occurs in women aging twenty five to thirty five. Most cases of cervical dysplasia are caused by human papilloma virus (HPV). Factors contributing to cervical dysplasia include using immunosuppressants and smoking. Signs and symptoms include genital warts, abnormal bleeding, spotting after intercourse, vaginal discharge and low back pain.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Cervical Intraepithelial Neoplasia (CIN) - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Cervical Intraepithelial Neoplasia (CIN) (Women's Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Cervical Intraepithelial Neoplasia (CIN) (Women's Health) pipeline guide also reviews of key players involved in therapeutic development for Cervical Intraepithelial Neoplasia (CIN) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 14, 6, 5 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 3, 2 and 4 molecules, respectively.

Cervical Intraepithelial Neoplasia (CIN) (Women's Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Cervical Intraepithelial Neoplasia (CIN) (Women's Health).

The pipeline guide reviews pipeline therapeutics for Cervical Intraepithelial Neoplasia (CIN) (Women's Health) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Cervical Intraepithelial Neoplasia (CIN) (Women's Health) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Cervical Intraepithelial Neoplasia (CIN) (Women's Health) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Cervical Intraepithelial Neoplasia (CIN) (Women's Health)

REASONS TO BUY

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Cervical Intraepithelial Neoplasia (CIN) (Women's Health).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Cervical Intraepithelial Neoplasia (CIN) (Women's Health) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying

prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

- Introduction
- Global Markets Direct Report Coverage
- Cervical Intraepithelial Neoplasia (CIN) - Overview
- Cervical Intraepithelial Neoplasia (CIN) - Therapeutics Development Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Cervical Intraepithelial Neoplasia (CIN) - Therapeutics Assessment
 - Assessment by Target
 - Assessment by Mechanism of Action
 - Assessment by Route of Administration
 - Assessment by Molecule Type
- Cervical Intraepithelial Neoplasia (CIN) - Companies Involved in Therapeutics Development
 - Altum Pharmaceuticals Inc
 - Antiva Biosciences Inc
 - Bioleaders Corp
 - Brooklyn ImmunoTherapeutics LLC
 - CEL-SCI Corp
 - Douglas Pharmaceuticals Ltd
 - Elicio Therapeutics
 - Genexine Inc
 - GenoLac BL Corp
 - Hefei Ruichengsheng Biotechnology Co Ltd
 - Inovio Pharmaceuticals Inc
 - KinoPharma Inc
 - Novan Inc
 - Papivax LLC
 - PDS Biotechnology Corp
 - Redbiotec AG
 - Shanghai Bovax Biotechnology Co Ltd
 - Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
 - Shanghai Institute of Biological Products Co Ltd
 - THEVAX Genetics Vaccine USA Inc
 - Transgene SA

Vaccibody AS

Vaxart Inc

ViciniVax BV

Cervical Intraepithelial Neoplasia (CIN) - Drug Profiles

(bivalimogene ralaplasmid + mavilimogene ralaplasmid) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(lopinavir + ritonavir) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ABI-1968 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

aminolevulinic acid hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AP-001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BLSILSB-710c - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BLSPGAC-10 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cellular Immunotherapy for Human Papillomavirus Infections - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cellular Immunotherapy to Target HPV Protein E6 and E7 for Cervical Intraepithelial Neoplasia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

efineptakin alfa - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Enzymes to Inhibit HPV E6 and E7 for Cervical Intraepithelial Neoplasia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapy for Human Papilloma Virus Associated Cervical Intraepithelial Neoplasia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GLBL-101c - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GX-188E - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

human papillomavirus (9 valent) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

human papillomavirus [serotypes 16, 18, 52, 58] (tetravalent, virus like particle) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IGMCK-16E7 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IRX-2 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Multikine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NSC-721689 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PDS-0101 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PVX-01 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PVX-2 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RKP-00156 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RONC-3 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tipapkinogene sovacivec - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TVGV-1 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine to Target E7 for HPV Associated Cervical Intraepithelial Neoplasia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine to Target HPV E6 for Cervical Intraepithelial Neoplasia And HPV Associated Head And Neck Squamous Cell Carcinoma - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VB-1016 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VED-001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vvax-001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VXAHPV-16.1 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

WH-504 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

WH-602 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ZFN-603 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ZFN-758 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cervical Intraepithelial Neoplasia (CIN) - Dormant Projects

Cervical Intraepithelial Neoplasia (CIN) - Discontinued Products

Cervical Intraepithelial Neoplasia (CIN) - Product Development Milestones

Featured News & Press Releases

Dec 03, 2019: PDS Biotechnology to present at the 12th Annual LD Micro Main Event

Nov 25, 2019: PDS Biotechnology to present at the World Vaccine & Immunotherapy Congress West Coast 2019

Nov 06, 2019: PDS Biotechnology accepted for oral presentation at the 34th Annual Society for Immunotherapy of Cancer Annual Meeting

Oct 01, 2019: PDS Biotechnology prioritizes development of PDS0101 in advanced cancers following promising phase 1 clinical outcome data

Sep 19, 2019: PDS Biotechnology reports clinical data for its novel immunotherapy PDS0101 in follow up to phase 1 human trial

Jun 26, 2019: Inovio completes enrollment of VGX-3100 phase 3 trial (reveal 1) for the treatment of HPV-related cervical pre-cancer

Jun 05, 2019: Peer-reviewed publication confirms the potential of Transgene' TG4001

May 06, 2019: Inovio receives European Medicines Agency Certification for quality and non-clinical data for its Phase 3 product, VGX-3100

Apr 17, 2019: Inovio's phase 3 HPV immunotherapy selected as "Best Therapeutic Vaccine" at World Vaccine Congress

Apr 03, 2019: Therapy completely clears HPV in one-third of cervical precancers

Mar 25, 2019: Positive 12-month results from phase IIa clinical study in high grade cervical dysplasia provides proof-of-concept for Vaccibody's immunotherapy platform and lead candidate VB10.16

Feb 27, 2019: vaccibody as to present data on vb10.16 at upcoming American Association for Cancer Research Annual Meeting

Dec 06, 2018: Study tests new vaccine for precancerous cervical cells

Apr 26, 2018: Vaccibody Announces Strong Killer T Cell Responses (Cd8+) In Vb10.16 Vaccinated Patients Further Strengthening The Strong Potential Of Their Vaccine

Technology Platform; Presenting At European Neoantigen Summit Amsterdam

Feb 14, 2018: IRX Therapeutics Announces Initiation of Phase 2 Clinical Trial of IRX-2 in Squamous Cervical or Vulvar Intraepithelial Neoplasia 3

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

[Contact Us](#)
[Disclaimer](#)

List Of Tables

LIST OF TABLES

Number of Products under Development for Cervical Intraepithelial Neoplasia (CIN), H2 2019

Number of Products under Development by Companies, H2 2019

Number of Products under Development by Universities/Institutes, H2 2019

Products under Development by Companies, H2 2019

Products under Development by Companies, H2 2019 (Contd..1), H2 2019

Products under Development by Universities/Institutes, H2 2019

Number of Products by Stage and Target, H2 2019

Number of Products by Stage and Mechanism of Action, H2 2019

Number of Products by Stage and Route of Administration, H2 2019

Number of Products by Stage and Molecule Type, H2 2019

Cervical Intraepithelial Neoplasia (CIN) - Pipeline by Altum Pharmaceuticals Inc, H2 2019

Cervical Intraepithelial Neoplasia (CIN) - Pipeline by Antiva Biosciences Inc, H2 2019

Cervical Intraepithelial Neoplasia (CIN) - Pipeline by Bioleaders Corp, H2 2019

Cervical Intraepithelial Neoplasia (CIN) - Pipeline by Brooklyn ImmunoTherapeutics LLC, H2 2019

Cervical Intraepithelial Neoplasia (CIN) - Pipeline by CEL-SCI Corp, H2 2019

Cervical Intraepithelial Neoplasia (CIN) - Pipeline by Douglas Pharmaceuticals Ltd, H2 2019

Cervical Intraepithelial Neoplasia (CIN) - Pipeline by Elicio Therapeutics, H2 2019

Cervical Intraepithelial Neoplasia (CIN) - Pipeline by Genexine Inc, H2 2019

Cervical Intraepithelial Neoplasia (CIN) - Pipeline by GenoLac BL Corp, H2 2019

Cervical Intraepithelial Neoplasia (CIN) - Pipeline by Hefei Ruichengsheng Biotechnology Co Ltd, H2 2019

Cervical Intraepithelial Neoplasia (CIN) - Pipeline by Inovio Pharmaceuticals Inc, H2 2019

Cervical Intraepithelial Neoplasia (CIN) - Pipeline by KinoPharma Inc, H2 2019

Cervical Intraepithelial Neoplasia (CIN) - Pipeline by Novan Inc, H2 2019

Cervical Intraepithelial Neoplasia (CIN) - Pipeline by Papivax LLC, H2 2019

Cervical Intraepithelial Neoplasia (CIN) - Pipeline by PDS Biotechnology Corp, H2 2019

Cervical Intraepithelial Neoplasia (CIN) - Pipeline by Redbiotec AG, H2 2019

Cervical Intraepithelial Neoplasia (CIN) - Pipeline by Shanghai Bovax Biotechnology Co Ltd, H2 2019

Cervical Intraepithelial Neoplasia (CIN) - Pipeline by Shanghai Fudan-Zhangjiang Bio-

Pharmaceutical Co Ltd, H2 2019

Cervical Intraepithelial Neoplasia (CIN) - Pipeline by Shanghai Institute of Biological Products Co Ltd, H2 2019

Cervical Intraepithelial Neoplasia (CIN) - Pipeline by THEVAX Genetics Vaccine USA Inc, H2 2019

Cervical Intraepithelial Neoplasia (CIN) - Pipeline by Transgene SA, H2 2019

Cervical Intraepithelial Neoplasia (CIN) - Pipeline by Vaccibody AS, H2 2019

Cervical Intraepithelial Neoplasia (CIN) - Pipeline by Vaxart Inc, H2 2019

Cervical Intraepithelial Neoplasia (CIN) - Pipeline by ViciniVax BV, H2 2019

Cervical Intraepithelial Neoplasia (CIN) - Dormant Projects, H2 2019

Cervical Intraepithelial Neoplasia (CIN) - Discontinued Products, H2 2019

List Of Figures

LIST OF FIGURES

Number of Products under Development for Cervical Intraepithelial Neoplasia (CIN), H2 2019

Number of Products under Development by Companies, H2 2019

Number of Products under Development by Universities/Institutes, H2 2019

Number of Products by Top 10 Targets, H2 2019

Number of Products by Stage and Top 10 Targets, H2 2019

Number of Products by Mechanism of Actions, H2 2019

Number of Products by Stage and Mechanism of Actions, H2 2019

Number of Products by Top 10 Routes of Administration, H2 2019

Number of Products by Stage and Top 10 Routes of Administration, H2 2019

Number of Products by Top 10 Molecule Types, H2 2019

Number of Products by Stage and Top 10 Molecule Types, H2 2019

COMPANIES MENTIONED

Altum Pharmaceuticals Inc

Antiva Biosciences Inc

Bioleaders Corp

Brooklyn ImmunoTherapeutics LLC

CEL-SCI Corp

Douglas Pharmaceuticals Ltd

Elicio Therapeutics

Genexine Inc

GenoLac BL Corp

Hefei Ruichengsheng Biotechnology Co Ltd

Inovio Pharmaceuticals Inc

KinoPharma Inc

Novan Inc

Papivax LLC

PDS Biotechnology Corp

Redbiotec AG

Shanghai Bovax Biotechnology Co Ltd

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd

Shanghai Institute of Biological Products Co Ltd

THEVAX Genetics Vaccine USA Inc

I would like to order

Product name: Cervical Intraepithelial Neoplasia (CIN) - Pipeline Review, H2 2019

Product link: <https://marketpublishers.com/r/C9B17F35E21EN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/C9B17F35E21EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970